|Day's range||32.03 - 32.24|
|52-week range||25.25 - 36.82|
|PE ratio (TTM)||22.08|
|Dividend & yield||1.03 (3.18%)|
|1y target est||N/A|
A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval this year. Roche received a positive opinion for the treatment from the EMA's Committee for Medicinal Products for Human Use (CHMP). Tecentriq, which Roche has designed to help the immune system find and kill tumours that otherwise may avoid detection, won approval in the United States this year as an initial treatment for bladder cancer.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.